Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
Abstract Background Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment. Objective To evaluate the therapeutic efficacy of the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-024-05984-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863321473843200 |
|---|---|
| author | Ruohong Lin Jiaxing Cheng Jinlong Zhao Liang Zhou Jian Li Xinchun Yang |
| author_facet | Ruohong Lin Jiaxing Cheng Jinlong Zhao Liang Zhou Jian Li Xinchun Yang |
| author_sort | Ruohong Lin |
| collection | DOAJ |
| description | Abstract Background Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment. Objective To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model. And quantitative assessment of the interaction between TB01 and TAS-102 in the treatment based on pharmacological effects. Methods This study utilized the human CRC HCT-116 xenograft nude mouse model to evaluate the antitumor effects of TAS-102 and TB01, both as mono-therapies and in combination therapies. Results The combination therapy not only demonstrated significantly inhibited tumor growth in a dose-dependent manner, but also seems to reduce the common toxicity associated with such treatments, as shown by the maintenance of body weights in the treated mice. Conclusion The synergistic effect observed from the combined use of TAS-102 and TB01 suggests a promising new treatment avenue for refractory CRC patients, meriting further investigation and potential clinical application. |
| format | Article |
| id | doaj-art-f57727f356544e0a86f1193be35b99b9 |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-f57727f356544e0a86f1193be35b99b92025-02-09T12:10:27ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352024-12-01151111110.1007/s00432-024-05984-zAnticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancerRuohong Lin0Jiaxing Cheng1Jinlong Zhao2Liang Zhou3Jian Li4Xinchun Yang5Zhuhai Tengbai Pharmaceutical Co., LtdZhuhai Tengbai Pharmaceutical Co., LtdZhuhai Tengbai Pharmaceutical Co., LtdZhuhai Tengbai Pharmaceutical Co., LtdState Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and TechnologyZhuhai Tengbai Pharmaceutical Co., LtdAbstract Background Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment. Objective To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model. And quantitative assessment of the interaction between TB01 and TAS-102 in the treatment based on pharmacological effects. Methods This study utilized the human CRC HCT-116 xenograft nude mouse model to evaluate the antitumor effects of TAS-102 and TB01, both as mono-therapies and in combination therapies. Results The combination therapy not only demonstrated significantly inhibited tumor growth in a dose-dependent manner, but also seems to reduce the common toxicity associated with such treatments, as shown by the maintenance of body weights in the treated mice. Conclusion The synergistic effect observed from the combined use of TAS-102 and TB01 suggests a promising new treatment avenue for refractory CRC patients, meriting further investigation and potential clinical application.https://doi.org/10.1007/s00432-024-05984-zColorectal cancerTrifluridine/Tipiracil (TAS-102)PEP06 (TB01)Combination therapySynergistic effect |
| spellingShingle | Ruohong Lin Jiaxing Cheng Jinlong Zhao Liang Zhou Jian Li Xinchun Yang Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer Journal of Cancer Research and Clinical Oncology Colorectal cancer Trifluridine/Tipiracil (TAS-102) PEP06 (TB01) Combination therapy Synergistic effect |
| title | Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer |
| title_full | Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer |
| title_fullStr | Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer |
| title_full_unstemmed | Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer |
| title_short | Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer |
| title_sort | anticancer effects of pep06 tb01 in combination with trifluridine tipiracil tas 102 in a xenograft model of human colorectal cancer |
| topic | Colorectal cancer Trifluridine/Tipiracil (TAS-102) PEP06 (TB01) Combination therapy Synergistic effect |
| url | https://doi.org/10.1007/s00432-024-05984-z |
| work_keys_str_mv | AT ruohonglin anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer AT jiaxingcheng anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer AT jinlongzhao anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer AT liangzhou anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer AT jianli anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer AT xinchunyang anticancereffectsofpep06tb01incombinationwithtrifluridinetipiraciltas102inaxenograftmodelofhumancolorectalcancer |